Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Attend and Present at Upcoming September Investor Conferences

Wednesday, September 6, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. (DTIL) has announced its participation in upcoming investor conferences. The company's management will present insights into its proprietary ARCUS platform, which focuses on in vivo gene editing therapies. This engagement reflects the company's commitment to fostering investor relations and showcasing its innovative technologies.
Price reaction · baseline $14.1 (2023-09-05 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-6.4%
day 1 · peak
-12.7%
day 3
-8.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively engaging with investors.
  • Participation in multiple conferences indicates strong market interest.
  • The company's proprietary ARCUS platform highlights innovative gene editing technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Sep. 6, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), a gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that members of management will participate in the following investor conferences in

Frequently Asked Questions

What is the focus of Precision BioSciences?

Precision BioSciences focuses on gene editing using its proprietary ARCUS platform.

When will Precision BioSciences participate in investor conferences?

Precision BioSciences will participate in investor conferences in September.

What does the ARCUS platform do?

The ARCUS platform is designed for developing in vivo gene editing therapies.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences ARCUS platform gene editing investor conferences
Last updated: Sep 6, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →